Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)

This multicenter, randomized, double-blind, placebo-controlled study assessed ambrisentan or placebo in patients with inoperable chronic thromboembolic pulmonary hypertension. Futility of enrollment led to early termination. Trends of improvement in favor of ambrisentan versus placebo in the primary...

Descripción completa

Detalles Bibliográficos
Autores principales: Escribano-Subias, Pilar, Bendjenana, Hakim, Curtis, Paula S., Lang, Irene, Noordegraaf, Anton Vonk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540507/
https://www.ncbi.nlm.nih.gov/pubmed/30957635
http://dx.doi.org/10.1177/2045894019846433
_version_ 1783422634607771648
author Escribano-Subias, Pilar
Bendjenana, Hakim
Curtis, Paula S.
Lang, Irene
Noordegraaf, Anton Vonk
author_facet Escribano-Subias, Pilar
Bendjenana, Hakim
Curtis, Paula S.
Lang, Irene
Noordegraaf, Anton Vonk
author_sort Escribano-Subias, Pilar
collection PubMed
description This multicenter, randomized, double-blind, placebo-controlled study assessed ambrisentan or placebo in patients with inoperable chronic thromboembolic pulmonary hypertension. Futility of enrollment led to early termination. Trends of improvement in favor of ambrisentan versus placebo in the primary and some secondary endpoints were observed; adverse event profiles were similar between groups.
format Online
Article
Text
id pubmed-6540507
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-65405072019-06-12 Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) Escribano-Subias, Pilar Bendjenana, Hakim Curtis, Paula S. Lang, Irene Noordegraaf, Anton Vonk Pulm Circ Research Letter This multicenter, randomized, double-blind, placebo-controlled study assessed ambrisentan or placebo in patients with inoperable chronic thromboembolic pulmonary hypertension. Futility of enrollment led to early termination. Trends of improvement in favor of ambrisentan versus placebo in the primary and some secondary endpoints were observed; adverse event profiles were similar between groups. SAGE Publications 2019-05-20 /pmc/articles/PMC6540507/ /pubmed/30957635 http://dx.doi.org/10.1177/2045894019846433 Text en © The Author(s) 2019 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Research Letter
Escribano-Subias, Pilar
Bendjenana, Hakim
Curtis, Paula S.
Lang, Irene
Noordegraaf, Anton Vonk
Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
title Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
title_full Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
title_fullStr Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
title_full_unstemmed Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
title_short Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
title_sort ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (cteph)
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540507/
https://www.ncbi.nlm.nih.gov/pubmed/30957635
http://dx.doi.org/10.1177/2045894019846433
work_keys_str_mv AT escribanosubiaspilar ambrisentanfortreatmentofinoperablechronicthromboembolicpulmonaryhypertensioncteph
AT bendjenanahakim ambrisentanfortreatmentofinoperablechronicthromboembolicpulmonaryhypertensioncteph
AT curtispaulas ambrisentanfortreatmentofinoperablechronicthromboembolicpulmonaryhypertensioncteph
AT langirene ambrisentanfortreatmentofinoperablechronicthromboembolicpulmonaryhypertensioncteph
AT noordegraafantonvonk ambrisentanfortreatmentofinoperablechronicthromboembolicpulmonaryhypertensioncteph

Ejemplares similares